Morgan Stanley (MS)
| Symbol(Simbol) | Last Trade | Name | Price | Change |
| Developed on a JamUba, Inc. solution.E-mail cs@ws-review.com for details. Data delayed.Information displayed should not be used for trading decisions. | ||||
Morgan Stanley (NYSE: MS) is a global financial services provider headquartered in New York City, New York, United States. It serves a diversified group of corporations, governments, financial institutions, and individuals. Morgan Stanley also operates in 33 countries around the world with 600 offices, with an approximate employee workforce of 45,000.The company reports US$779 billion as assets under its management.
The corporation, formed by J.P. Morgan & Co. employees Henry S. Morgan (grandson of J.P. Morgan), Harold Stanley and others, came into existence on September 16, 1935. In its first year the company operated with a 24% market share (US$1.1 billion) in public offerings and private placements. The main areas of business for the firm today are Global Wealth Management, Institutional Securities and Investment Management.
The company found itself in the midst of a management crisis in the late 1990s that saw it lose a lot of talent and competence and ultimately saw the firing of its then CEO Philip Purcell in 2005.
On September 21, 2008, it was reported that the Federal Reserve allowed Morgan Stanley to change its status from investment bank to bank holding company. On September 29, 2008, it was announced that Mitsubishi UFJ Financial Group, Japan's largest bank, will take a stake of $9 billion in Morgan Stanley equity. In the midst of the October 2008 stock market crash, concerns over the completion of the Mitsubishi deal caused a dramatic fall in Morgan Stanley's stock price to levels last seen in 1994. The stock grew considerably after Mitsubishi UFJ closed the deal to buy 21% of Morgan Stanley on October 14, 2008.
Forbes.com: ms
- Pranking Goldman's Lucas Van Praag
The sharp-tongued spokesman is the subject of a blistering Twitter parody.
- The Thrill Is Gone, No More Fun In Financials
If you've waited a year to be sure the rally in bank stocks was for real, you've missed the bounce.
- Roche, Biogen Idec End Drug Trial
Shares of Roche are doing fine, compared to drug cohorts AstraZeneca and Lexicon.
- New Exit Strategies For Venture Capitalists
Public offerings are still few and far between. So how do the VCs plan to make hay?
- Battle Of Taiwan's Tech Titans
Barry Lam's Quanta Computer may fall even further behind its domestic rival.
